Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial.
In a multicentre placebo-controlled double-blind study 61 patients with spinal cord injuries and detrusor hyperreflexia were treated: 20 mg trospium chloride was given twice daily over a period of 3 weeks. Pre- and posttreatment urodynamic measurements demonstrated large improvements in maximum cystometric capacity (mean = 138.1 ml), decreased maximum detrusor pressure (mean = -37.8 cm H2O) and an increase in compliance (mean = 12.1 ml/cm H2O) in the treatment group. Urodynamic parameters in the placebo group remained substantially unchanged. Comparisons between the two groups revealed highly significant differences for these parameters (all, p less than 0.001). No effect on maximum flow rate and residual urine was detected in either group. The incidence of spontaneously reported side-effects was extremely low and comparable for both groups.
Stöhrer
M
M
Berufsgenossenschaftliche Unfallklinik, Murnau, BRD.
Bauer
P
P
Giannetti
B M
BM
Richter
R
R
Burgdörfer
H
H
Mürtz
G
G
D000328:Adult; D001561:Benzilates; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009662:Nortropanes / Q000009:adverse effects / Q000627:therapeutic use*; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D011312:Pressure; D013119:Spinal Cord Injuries / Q000150:complications*; D001743:Urinary Bladder / Q000503:physiopathology; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014563:Urodynamics
D001561:Benzilates; D009662:Nortropanes; D010276:Parasympatholytics; C003330:trospium chloride